Healthcare & Medical
Category / Healthcare & Medical
NEEDHAM, MA,: NEEDHAM, MA, Feb 2, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glyco ...
NEEDHAM, MASS.,: Company reiterates focus on advancing ProLectin-M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative disease ...
TOKYO: TANAKA will showcase platinum- and other precious metal-based materials, backed by 140 years of expertise, advanced processing technologies, and a stable global supply system ...
SINGAPORE: SINGAPORE, January 7, 2026 - (ACN Newswire) - Leading regional private healthcare provider group Fullerton Health (“Fullerton Health” or the “Group”) said today it has successfully acquired on ...
SINGAPORE: SINGAPORE, Dec 24, 2025 - (ACN Newswire) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, an ...
HONG KONG: HONG KONG, December 15, 2025 - (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading ...
HONG KONG: HONG KONG, Oct 14, 2025 - (ACN Newswire) – Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen ...
HONG KONG: HONG KONG, Oct 30, 2025 - (ACN Newswire) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”), a subsidiary of NovaBridge Bio ...
HONG KONG:
HONG KONG, December 12, 2025 - (ACN Newswire) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), h ...
PETALING JAYA, Malaysia,: Partnership drives clinical research, hands-on student training, and access to cutting-edge medical technologies
...
Hong Kong: To Accelerate Commercialisation and Global Expansion
...
Hong Kong: HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus ...
Hong Kong: HONG KONG, Oct 9, 2025 - (ACN Newswire) - Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatmen ...
TOKYO: TOKYO, Oct 29, 2025 - (JCN Newswire) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of ...
TOKYO & HAMBURG: THUNDERBEAT™ II features the versatility of three energy modes to support surgeons in adapting to challenging clinical conditions ...
BANDUNG, INDONESIA: The 26th DCVMN Annual General Meeting, held in Bali on 29-31 October, marks a moment for Indonesia to reaffirm leadership in global health diplomacy ...
TOKYO: TOKYO, Oct 21, 2025 - (JCN Newswire) - Olympus Corporation (Olympus), today announced that the feasibility study project entitled “Feasibility study on the development of Japanese digitalized endosc ...
